<DOC>
	<DOC>NCT01673360</DOC>
	<brief_summary>To monitor post-market performance through evaluation of short and long-term performance via: - Efficacy - Safety - Patient reported outcomes</brief_summary>
	<brief_title>Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices</brief_title>
	<detailed_description>As this is a post-market registry on market approved devices, there will be no formal hypothesis testing. However, points of evaluation will include: - Characterize the efficacy of the AMS market approved female pelvic health products using standard of care outcome measures and validated quality of life questionnaires - Characterize the type, severity, and rate of adverse events related to each AMS market approved female pelvic health product - Collect concomitant procedural data related to the pelvic floor area</detailed_description>
	<mesh_term>Prolapse</mesh_term>
	<mesh_term>Pelvic Organ Prolapse</mesh_term>
	<mesh_term>Urinary Incontinence, Stress</mesh_term>
	<criteria>Patients must meet all of the following criteria to be considered for inclusion in the registry. Have a signed Informed Consent Form Have a signed HIPAA Authorization Form or equivalent Patient Privacy Form if required outside of the US Is a female at least 18 years of age Is scheduled to receive at least one (1) AMS market approved female pelvic health implantable product. Is able and willing to participate in the registry Patients will be excluded from the registry if any one of the following criteria is met. Patients are contraindicated to receive the target AMS market approved female pelvic health product per the product's IFU</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>vaginal repair</keyword>
	<keyword>urinary slings</keyword>
	<keyword>POP</keyword>
	<keyword>SUI</keyword>
	<keyword>prolapse</keyword>
	<keyword>incontinence</keyword>
</DOC>